Peter P. Pfreundschuh is CFO at UroGen Pharma Ltd. (URGN). They have made 14 open-market trades across 3 companies since 2019, most recently 2025-09-16.
CIK 0001585839
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VYGR | SELL | 2024-02-21 | 2024-02-22 | $7.46 | $28K | +18.2% | +20.3% | +7.8% |
| VYGR | SELL | 2023-10-03 | 2023-10-05 | $6.99 | $190K | +6.3% | -8.7% | +51.5% |
| FREQ | SELL | 2022-02-18 | 2022-02-23 | $3.70 | $11K | -26.5% | -27.2% | -62.8% |
| FREQ | SELL | 2022-02-16 | 2022-02-18 | $4.31 | $11K | -38.8% | -37.7% | -66.5% |
| FREQ | SELL | 2022-02-15 | 2022-02-16 | $4.33 | $6K | -37.9% | -42.4% | -70.0% |
| URGN | SELL | 2020-10-15 | 2020-10-16 | $21.77 | $52K | -4.6% | -0.4% | -9.0% |
| URGN | SELL | 2020-09-01 | 2020-09-01 | $22.82 | $12K | +2.2% | -6.7% | -1.6% |
| URGN | SELL | 2020-07-27 | 2020-07-28 | $23.51 | $3K | +0.3% | -14.0% | -8.8% |
| URGN | SELL | 2020-05-20 | 2020-05-20 | $25.07 | $9K | -2.1% | +13.5% | -9.5% |
| URGN | SELL | 2020-04-27 | 2020-04-28 | $24.35 | $3K | -11.3% | -9.9% | -10.5% |
| URGN | SELL | 2020-02-20 | 2020-02-24 | $29.68 | $11K | -1.1% | -38.6% | -14.3% |
| URGN | SELL | 2020-01-27 | 2020-01-28 | $29.28 | $20K | -1.9% | -11.1% | -18.0% |
| URGN | SELL | 2019-11-20 | 2019-11-22 | $28.41 | $10K | +3.1% | +14.6% | +1.4% |
| URGN | SELL | 2019-08-20 | 2019-08-22 | $33.07 | $47K | +6.0% | +5.7% | -5.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.